Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/18/2012EP1829542B1 Peroxisome proliferator-activated receptor (ppar) activator and drug, supplement, functional food and food additive using the same
07/18/2012EP1809243B1 Aerosol suspension formulations containing tg 227 ea as a propellant
07/18/2012EP1720554B1 Use of meloxicam for the treatment of respiratory diseases in pigs
07/18/2012EP1701932B1 Tolterodine, compositions and uses thereof, and preparation of the same
07/18/2012EP1669065B1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient
07/18/2012EP1608648B1 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
07/18/2012EP1542701B1 Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
07/18/2012EP1470148B1 Double-stranded oligonucleotides
07/18/2012EP1437961B1 Methods of suppressing microglial activation
07/18/2012EP1389909B1 Antimicrobial compounds and methods for their use
07/18/2012CN202336063U 一种软胶囊 A soft capsule
07/18/2012CN1951917B Pyridinone derivatives for treatment of atherosclerosis
07/18/2012CN1935260B Human antibodies that bind human tnfalpha
07/18/2012CN1923191B Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases
07/18/2012CN1917890B Composition and method for use in cartilage affecting conditions
07/18/2012CN1903214B Ointment containing red precipitate
07/18/2012CN1835937B Novel thiazoline derivatives as selective androgen receptor modulators (SARMS)
07/18/2012CN1794983B Aqueous olanexidine solution, method of preparing the same, and disinfectant
07/18/2012CN1753886B Process for producing acid adduct salt of polyacidic base compound
07/18/2012CN1738636B Use of enzyme inhibitors with aminopeptidase N and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
07/18/2012CN1732163B Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
07/18/2012CN1688192B Immunostimulatory nucleic acids
07/18/2012CN1639130B Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
07/18/2012CN1531533B Crystalline form of omeprazole
07/18/2012CN1473035B Compositions containing substained-release fine grains for tablets quickly disintegrable in oral cavity and process for producing same
07/18/2012CN1449445B Ev-vegf nucleic acids and polypeptides and methods of use
07/18/2012CN1443167B Azacyclic compounds for use in treatment of 5-serotonin related diseases
07/18/2012CN1440408B Inhibitors of human phosphatidyl-inositol 3-kinase delta
07/18/2012CN102597779A Method for determination of sensitivity to anti-cancer ag
07/18/2012CN102597778A Method for determination of sensitivity to anti-cancer ag
07/18/2012CN102597762A Anticancer agent sensitivity-determining marker
07/18/2012CN102597239A Sirna compounds comprising terminal substitutions
07/18/2012CN102596991A Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
07/18/2012CN102596985A 17-hydroxy-17-pentafluorethyl-estra-4, 9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases
07/18/2012CN102596983A Bridged artificial nucleoside and nucleotide
07/18/2012CN102596982A Agent for inhibiting thickening of peritoneal membrane
07/18/2012CN102596981A Antibacterial aminoglycoside analogs
07/18/2012CN102596977A Triptolide prodrugs
07/18/2012CN102596969A Condensed quinolines as protein kinase modulators
07/18/2012CN102596965A Pyrrolo [3,2-E] [1,2,4] triazolo [1,5-A] pyrimidines derivatives as inhibitors of microglia activation
07/18/2012CN102596964A Pyrrolo [3,2-E] [1,2,4] triazolo [1,5-A] pyrimidines derivatives as inhibitors of microglia activation
07/18/2012CN102596963A Ether derivatives of bicyclic heteroaryls
07/18/2012CN102596962A Inhibitors of JAK
07/18/2012CN102596961A Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
07/18/2012CN102596960A Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
07/18/2012CN102596959A Pyrrolo [1, 2-b] pyridazine derivatives as JANUS kinase inhibitors
07/18/2012CN102596957A Substituted pyrazolo[1,5- a]pyrimidine compounds as TRK kinase inhibitors
07/18/2012CN102596956A Novel method for preparing entecavir and intermediate used therein
07/18/2012CN102596955A Histamine H3 inverse agonists and antagonists and methods of use thereof
07/18/2012CN102596954A JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
07/18/2012CN102596953A Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
07/18/2012CN102596951A Heterocyclic sulfonamide derivatives useful as mek inhibitors
07/18/2012CN102596949A 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
07/18/2012CN102596946A Antiviral compounds and methods of making and using thereof
07/18/2012CN102596944A Substituted piperidines
07/18/2012CN102596942A Cyclic triazo sodium channel blockers
07/18/2012CN102596941A Compounds for the treatment of dyslipidemia and related diseases
07/18/2012CN102596938A Alkyl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
07/18/2012CN102596937A Compounds and compositions as protein kinase inhibitors
07/18/2012CN102596936A Antiviral compounds
07/18/2012CN102596935A Compounds useful for treating premature aging and in particular progeria
07/18/2012CN102596934A Heteroaryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
07/18/2012CN102596932A Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
07/18/2012CN102596929A Treatment of macular degeneration
07/18/2012CN102596923A 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
07/18/2012CN102596921A Novel compounds
07/18/2012CN102596919A Aromatase inhibitor
07/18/2012CN102596918A Aryl substituted arylindenopyrimidines and their use as highly selective adenosine a2a receptor antagonists
07/18/2012CN102596917A Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate
07/18/2012CN102596916A N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
07/18/2012CN102596913A Cannabinoid receptor modulators
07/18/2012CN102596912A Process for preparing 1,3-disubstituted pyrazole compounds
07/18/2012CN102596911A Process for preparing aminale and their use for preparing 1,3-disubstituted pyrazole compounds
07/18/2012CN102596910A Androgen receptor modulating compounds
07/18/2012CN102596909A Positive allosteric modulators (PAM)
07/18/2012CN102596908A Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
07/18/2012CN102596905A 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
07/18/2012CN102596904A Protease inhibitors, compositions and methods of use
07/18/2012CN102596902A DP2 antagonist and uses thereof
07/18/2012CN102596898A Tetracycline compounds
07/18/2012CN102596896A Mexiletine amino acid and peptide prodrugs and uses thereof
07/18/2012CN102596322A Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
07/18/2012CN102596321A Alkynyl derivatives useful as dpp-1 inhibitors
07/18/2012CN102596256A Composition for treatment of pancreatic cancer
07/18/2012CN102596252A Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
07/18/2012CN102596251A High strength seamless alginate capsules
07/18/2012CN102596245A Combination therapy of an afucosylated CD20 antibody with bendamustine
07/18/2012CN102596226A Schistosomiasis vaccine compositions and methods of use
07/18/2012CN102596207A Hydrogel formulation comprising oxidative reductive potential water
07/18/2012CN102596206A Pharmaceutical composition for oral administration
07/18/2012CN102596205A Use of non-digestible oligosaccharides
07/18/2012CN102596204A Novel nucleic acid prodrugs and methods use thereof
07/18/2012CN102596203A Liquid pharmaceutical form of alkylphosphocholine and method of preparing same
07/18/2012CN102596202A New crystalline form of pemirolast
07/18/2012CN102596201A Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
07/18/2012CN102596200A Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
07/18/2012CN102596199A Ophthalmic pharmaceutical compositions of DP2 receptor antagonists
07/18/2012CN102596198A Pharmaceutical composition comprising indole compound
07/18/2012CN102596197A Combination therapy for treating proliferative diseases
07/18/2012CN102596196A Methods for inducing programmed cell death
1 ... 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 ... 7860